Clinical trial
Study Evaluating Refacto For Pharmacovigilance
NCT00195442 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195442 |
|---|---|
| Title | Study Evaluating Refacto For Pharmacovigilance |
| Official title | Pharmacovigilance Evaluation Of Refacto In Usual Care Settings |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Moroctocog alfa |
| Enrollment | 288 |
| Start date | Jul 1, 1999 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 11, 2011 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: